Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10990414 | 0.83 | GAA (0.67) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL18563358 | 0.81 | SIGMAR1 (0.61) | MEN1KMT2ATSHRSIGMAR1MC4R | |
| SCHEMBL867675 | 0.80 | GAA (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL7436149 | 0.80 | GAA (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL28349386 | 0.80 | GAA (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL28612690 | 0.80 | GAA (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL15320452 | 0.80 | GAA (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL27798357 | 0.79 | SIGMAR1 (0.62) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL31230952 | 0.78 | GAA (0.61) | GAAMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL31230950 | 0.78 | GAA (0.71) | GAAMEN1KMT2ATSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | GAA 2982/4885MEN1 3335/4885KMT2A 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.